EIF2AK3 and glioblastoma: With the exception of the lowest dose tested (1 μM) in U87 cells, incubation with the PERK inhibitor GSK-2606414 (PERKi) (1–20 μM) for 72 h had significant cytotoxic effects on GBM cells (Figure 5A,B).